IL296985A - Compositions and methods for the prevention and/or treatment of mitochondrial disease, including friedreich's ataxia - Google Patents
Compositions and methods for the prevention and/or treatment of mitochondrial disease, including friedreich's ataxiaInfo
- Publication number
- IL296985A IL296985A IL296985A IL29698522A IL296985A IL 296985 A IL296985 A IL 296985A IL 296985 A IL296985 A IL 296985A IL 29698522 A IL29698522 A IL 29698522A IL 296985 A IL296985 A IL 296985A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- infection
- skin
- ch2ch3
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/02—Quinones with monocyclic quinoid structure
- C07C50/06—Quinones with monocyclic quinoid structure with unsaturation outside the quinoid structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
- C07C50/28—Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063004639P | 2020-04-03 | 2020-04-03 | |
| PCT/US2021/025558 WO2021202986A1 (en) | 2020-04-03 | 2021-04-02 | Compositions and methods for the prevention and/or treatment of mitochondrial disease, including friedreich's ataxia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL296985A true IL296985A (en) | 2022-12-01 |
Family
ID=75728888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL296985A IL296985A (en) | 2020-04-03 | 2021-04-02 | Compositions and methods for the prevention and/or treatment of mitochondrial disease, including friedreich's ataxia |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12037350B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4126836A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023520462A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230005855A (cg-RX-API-DMAC10.html) |
| CN (4) | CN115996916B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021246142A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3176909A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL296985A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021202986A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022291142A1 (en) | 2021-06-10 | 2023-12-21 | Stealth Biotherapeutics Inc. | Compounds, compositions and methods for the prevention and/or treatment of various mitochondrial diseases or disorders, including friedreich's ataxia |
| US11541116B1 (en) | 2022-01-07 | 2023-01-03 | Kojin Therapeutics, Inc. | Methods and compositions for inducing ferroptosis in vivo |
| WO2024263742A1 (en) * | 2023-06-22 | 2024-12-26 | Stealth Biotherapeutics Inc. | Combination therapy for the treatment of friedreich's ataxia |
| AU2024300048A1 (en) * | 2023-07-21 | 2026-01-22 | Stealth Biotherapeutics Inc. | Methods, compositions and uses related to the treatment and prevention of leigh's syndrome |
| AU2024377199A1 (en) | 2023-11-09 | 2026-05-21 | Stealth Biotherapeutics Inc. | Cyclo-hexa-2,5-diene-1,4-diones for use in the treatment of cardiomyopathy |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JP3507486B2 (ja) | 1991-03-15 | 2004-03-15 | アムジエン・インコーポレーテツド | 顆粒球コロニー刺激因子の肺内投与 |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US5674534A (en) | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5716644A (en) | 1992-06-11 | 1998-02-10 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| CA2272971C (en) | 1998-10-29 | 2008-01-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Quinone derivatives for treating or preventing diseases associated with iron overload |
| US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
| WO2005033092A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
| EA035619B1 (ru) | 2005-06-01 | 2020-07-16 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Композиции для использования в способе лечения митохондриальных нарушений |
| JP2009508867A (ja) | 2005-09-15 | 2009-03-05 | エジソン ファーマシューティカルズ， インコーポレイテッド | ミトコンドリア病および関連した様態の治療ならびにエネルギーバイオマーカーの調節のための酸化還元活性治療剤のテイル改変体 |
| EP1986636B1 (en) | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| EP2332534B1 (en) | 2006-02-22 | 2018-11-14 | Bioelectron Technology Corporation | Phenol and benzoquinone derivatives for use in the treatment of mitochondrial diseases and modulation of energy biomarkers |
| WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| EP2303824B1 (en) | 2008-06-25 | 2015-03-25 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
| EP2344142B1 (en) | 2008-09-10 | 2024-06-26 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| WO2010051277A1 (en) | 2008-10-28 | 2010-05-06 | Edison Pharmaceuticals, Inc. | Process for the production of alpha-tocotrienol and derivatives |
| EP2246048A1 (en) | 2009-04-30 | 2010-11-03 | Santhera Pharmaceuticals (Schweiz) AG | Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis |
| NO2470168T3 (cg-RX-API-DMAC10.html) | 2009-08-26 | 2018-06-30 | ||
| US20130345312A1 (en) | 2010-08-06 | 2013-12-26 | Orion D. Jankowski | Treatment of mitochondrial diseases with naphthoquinones |
| HRP20161407T1 (hr) | 2010-08-16 | 2016-12-02 | Santhera Pharmaceuticals (Schweiz) Ag | Derivati benzokinona za liječenje mitohondrijskih bolesti oka |
| EP2606022A2 (en) | 2010-08-16 | 2013-06-26 | Santhera Pharmaceuticals (Schweiz) AG | Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function |
| WO2012068552A1 (en) | 2010-11-19 | 2012-05-24 | Edison Pharmaceuticals, Inc. | Methods for improving blood glucose control |
| WO2012170773A1 (en) | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
| KR102137450B1 (ko) | 2012-07-12 | 2020-07-27 | 콘드리온 아이피 비.브이. | 미토콘드리아 질환을 치료하기 위한 크로마닐 유도체 |
| CA2883879A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Quinone derivatives for use in the modulation of redox status of individuals |
| JP6367211B2 (ja) | 2012-11-16 | 2018-08-01 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | リソソーム蓄積症の改善物質としてのトコフェロール誘導体およびトコフェリルキノン誘導体 |
| JP2016515526A (ja) | 2013-03-15 | 2016-05-30 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化ストレス障害の処置のためのアルキル−ヘテロアリール置換されたキノン誘導体 |
| WO2015183963A2 (en) | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including redox-active parabenzoquinones and uses thereof |
| EP3377179B1 (en) | 2015-11-19 | 2021-04-07 | Concert Pharmaceuticals Inc. | Deuterated epi-743 |
| EP3389646A1 (en) | 2015-12-17 | 2018-10-24 | BioElectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| CA3011293A1 (en) | 2016-01-12 | 2017-07-20 | Ptc Therapeutics, Inc. | Tocopherol and tocotrienol quinone derivatives for increasing thiosulfate levels or decreasing hydrogen sulfide levels |
| WO2018191732A1 (en) * | 2017-04-14 | 2018-10-18 | Bioelectron Technology Corporation | Methods and compositions for treatment of inflammation and oxidative stress |
| JP7266304B2 (ja) | 2017-04-21 | 2023-04-28 | ユニヴァーシティー オブ タスマニア | 治療化合物および方法 |
| IL305687B2 (en) | 2017-12-15 | 2024-12-01 | Stealth Biotherapeutics Inc | Mitochondria-targeting peptides |
-
2021
- 2021-04-02 CA CA3176909A patent/CA3176909A1/en active Pending
- 2021-04-02 CN CN202180040296.8A patent/CN115996916B/zh active Active
- 2021-04-02 EP EP21722328.8A patent/EP4126836A1/en active Pending
- 2021-04-02 IL IL296985A patent/IL296985A/en unknown
- 2021-04-02 CN CN202510664780.8A patent/CN120554211A/zh active Pending
- 2021-04-02 JP JP2022559922A patent/JP2023520462A/ja active Pending
- 2021-04-02 CN CN202511246796.3A patent/CN121085765A/zh active Pending
- 2021-04-02 WO PCT/US2021/025558 patent/WO2021202986A1/en not_active Ceased
- 2021-04-02 US US17/221,463 patent/US12037350B2/en active Active
- 2021-04-02 CN CN202511246906.6A patent/CN121085756A/zh active Pending
- 2021-04-02 KR KR1020227038265A patent/KR20230005855A/ko active Pending
- 2021-04-02 AU AU2021246142A patent/AU2021246142A1/en active Pending
-
2024
- 2024-05-23 US US18/672,819 patent/US20240400588A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN120554211A (zh) | 2025-08-29 |
| EP4126836A1 (en) | 2023-02-08 |
| CN121085765A (zh) | 2025-12-09 |
| CA3176909A1 (en) | 2021-10-07 |
| US20210317146A1 (en) | 2021-10-14 |
| AU2021246142A1 (en) | 2022-10-20 |
| CN115996916B (zh) | 2025-09-23 |
| CN121085756A (zh) | 2025-12-09 |
| US12037350B2 (en) | 2024-07-16 |
| US20240400588A1 (en) | 2024-12-05 |
| JP2023520462A (ja) | 2023-05-17 |
| CN115996916A (zh) | 2023-04-21 |
| WO2021202986A1 (en) | 2021-10-07 |
| KR20230005855A (ko) | 2023-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5688819A (en) | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents | |
| US8017655B2 (en) | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents | |
| US10045997B2 (en) | Hypotensive lipid and timolol compositions and methods of using same | |
| RU2006125377A (ru) | Гетероциклические ингибиторы аспартилпротеазы | |
| AU2002312221A1 (en) | Hypotensive lipid (prostaglandin derivatives) and timolol compositions and methods of using same | |
| MX2025000291A (es) | Compuesto heterocíclico capaz de inhibir prmt5mta y uso del mismo | |
| JP2023520462A5 (cg-RX-API-DMAC10.html) | ||
| CA2023560C (en) | 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic acid anilides for the treatment of ocular diseases | |
| WO2011056744A4 (en) | IRE-1 α INHIBITORS | |
| RU2007125130A (ru) | Применение атазанавира для улучшения фармакокинетики лекарственных средств, метаболизируемых ugt1a1 | |
| AU734650B2 (en) | Ophthalmic preparations | |
| CA2373395A1 (en) | Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors | |
| EP2125773B1 (en) | Thiophene derivatives useful as medicaments for treating ocular hypertension | |
| EP0420606B1 (en) | Use of 2-cycloalkylamino oxazolines for reducing or maintaining intraocular pressure | |
| US5328933A (en) | Cyclopentane heptenylnitro and heptanylnitro-2-aliphatic or aryl aliphatic derivatives and homologues | |
| AU717104B2 (en) | Ocular depressor | |
| US20080051406A1 (en) | Brimonidine and timolol compositions | |
| CA2058258A1 (en) | Substituted benzene derivatives for use in the treatment of glaucoma | |
| AU741844B2 (en) | Thromboxane ligands | |
| CA2402597A1 (en) | Composition for use in treatment of ocular hypertension and glaucoma | |
| HUP0203213A2 (en) | Use of 2-imidazolyl substituted carbinols for production of medicaments for treatment or prophylaxis of ischaemic conditions | |
| US5189051A (en) | Treatment of glaucoma and ocular hypertension with pyrrole angiotensin-II receptor antagonists | |
| JP2005314348A (ja) | 顔面神経麻痺治療剤 | |
| KR20140050080A (ko) | N,n-디알킬알킬레닐 에스테르, 이의 조성물, 및 그의 사용 방법 | |
| JP2024538721A5 (cg-RX-API-DMAC10.html) |